Stockscreener 앱 받기
161.42
1.35%
2.15
전일 마감가:
$159.27
열려 있는:
$160.35
하루 거래량:
3.66M
Relative Volume:
1.24
시가총액:
$34.43B
수익:
$447.02M
순이익/손실:
$-1.18B
주가수익비율:
-26.11
EPS:
-6.1812
순현금흐름:
$-906.14M
1주 성능:
-8.27%
1개월 성능:
-19.56%
6개월 성능:
+54.34%
1년 성능:
+121.88%
1일 변동 폭
$158.39
$163.98
1주일 범위
$158.39
$175.12
52주 변동 폭
$60.40
$212.75
Insmed Inc Stock (INSM) Company Profile
명칭
Insmed Inc
전화
908-977-9900
주소
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
INSM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
161.42 | 33.97B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-19 | 재개 | Truist | Buy |
| 2025-12-04 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-10-28 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-08-20 | 개시 | William Blair | Outperform |
| 2025-08-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 개시 | Jefferies | Buy |
| 2025-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2024-04-23 | 개시 | Truist | Buy |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-07-26 | 개시 | Guggenheim | Buy |
| 2022-12-09 | 개시 | Mizuho | Buy |
| 2022-12-07 | 개시 | Barclays | Overweight |
| 2022-11-18 | 개시 | BofA Securities | Buy |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2021-12-06 | 개시 | JP Morgan | Overweight |
| 2021-10-19 | 재개 | Monness Crespi & Hardt | Buy |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-10-12 | 재개 | Stifel | Buy |
| 2019-09-03 | 개시 | Goldman | Buy |
| 2019-04-09 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-15 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-01-02 | 개시 | Canaccord Genuity | Buy |
| 2018-08-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | 개시 | Goldman | Neutral |
| 2018-04-23 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | 개시 | Morgan Stanley | Overweight |
| 2018-01-18 | 개시 | Credit Suisse | Neutral |
| 2017-09-05 | 재확인 | Evercore ISI | Outperform |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-07-11 | 개시 | Robert W. Baird | Outperform |
| 2016-03-15 | 개시 | Stifel | Buy |
| 2015-11-09 | 다운그레이드 | UBS | Buy → Neutral |
| 2015-10-06 | 재확인 | H.C. Wainwright | Buy |
| 2015-06-09 | 개시 | Citigroup | Neutral |
| 2014-03-26 | 재확인 | HC Wainwright | Buy |
모두보기
Insmed Inc 주식(INSM)의 최신 뉴스
Analysts’ Top Healthcare Picks: Insmed (INSM), Roche Holding AG (RHHVF) - The Globe and Mail
EULAV Asset Management Acquires Shares of 90,000 Insmed, Inc. $INSM - MarketBeat
Looking At Insmed's Recent Unusual Options Activity - Benzinga
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed IncorporatedINSM - marketscreener.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed IncorporatedINSM - PR Newswire
Nisa Investment Advisors LLC Acquires 8,261 Shares of Insmed, Inc. $INSM - MarketBeat
Aug Reactions: Can Insmed Incorporated expand into new markets2025 Price Action Summary & Short-Term High Return Strategies - baoquankhu1.vn
SG Americas Securities LLC Acquires 13,305 Shares of Insmed, Inc. $INSM - MarketBeat
Bank of America Securities Keeps Their Buy Rating on Insmed (INSM) - The Globe and Mail
Jobs Data: What is the long term forecast for Insmed Incorporated stockJuly 2025 Earnings & Safe Capital Allocation Plans - baoquankhu1.vn
Analysts Have Conflicting Sentiments on These Healthcare Companies: Establishment Labs Holdings (ESTA), Sarepta Therapeutics (SRPT) and Insmed (INSM) - The Globe and Mail
Insmed CEO William Lewis sells $3.2 million in shares By Investing.com - Investing.com South Africa
Insmed CEO William Lewis sells $3.2 million in shares - Investing.com
Insmed (NASDAQ:INSM) CEO William Lewis Sells 19,215 Shares - MarketBeat
Insmed (BIT:1INSM) Price Target Decreased by 14.88% to 185.76 - Nasdaq
Insmed Insider Sold Shares Worth $351,341, According to a Recent SEC Filing - marketscreener.com
INSMED Chair and CEO William Lewis Sells 19,215 Shares - TradingView — Track All Markets
Short Squeeze: How Insmed Incorporated stock performs after earningsWeekly Risk Summary & Safe Entry Zone Tips - moha.gov.vn
Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake - MSN
INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced - sharewise.com
Insmed Stock Pre-Market (+4.3%): Upbeat Analyst Day Highlights Strong BRINSUPRI™ Uptake & Pipeline - Trefis
MACD Signal: How Insmed Incorporated (IM8N) stock correlates with oil marketsTrade Entry Report & Smart Investment Allocation Insights - Bộ Nội Vụ
Rally Mode: Will Insmed Incorporated stock hit new highs in YEARQuarterly Performance Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Insmed stock soars as Brinsupri sales beat expectations by 116% - Investing.com Canada
Assessing Insmed (INSM) Valuation After Strong Multi‑Year Returns And Recent Share Price Pullback - simplywall.st
Insmed Incorporated (INSM): Growth Potential In Biotechnology With A 22.62% Upside - DirectorsTalk Interviews
Top Pharmaceutical Stocks To Follow TodayJanuary 11th - MarketBeat
Insmed (INSM) Stock Undervalued by 54.3% Based on DCF Analysis - Intellectia AI
Is It Too Late To Reassess Insmed (INSM) After Its Huge Share Price Surge? - Yahoo Finance
The Bull Case For Insmed (INSM) Could Change Following Bold 2025 Revenue Guidance HikeLearn Why - Yahoo Finance
What risks investors should watch in Insmed Incorporated stockJuly 2025 Momentum & Low Volatility Stock Suggestions - ulpravda.ru
Tangible book value per share of Insmed Incorporated – BX:IM8N - TradingView — Track All Markets
Jim Cramer on Insmed: "This one is worth keeping an eye on" - MSN
Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 - Reuters
Insmed (INSM) Surpasses Revenue Expectations with Strong Growth - GuruFocus
Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal - BioPharma Dive
Insmed (NASDAQ:INSM) Shares Gap UpStill a Buy? - MarketBeat
Insmed Maps Aggressive 2026: New Lung Disease Drug, Pipeline AdvancesInsmed (NASDAQ:INSM) - Benzinga
Insmed posts early 2025 revenue beating consensus (INSM:NASDAQ) - Seeking Alpha
Insmed Jumps on ‘Blowout’ Sales Beat for Bronchiectasis Drug Brinsupri - BioSpace
Insmed: Strong Brinsupri Launch, Solid Arikayce Performance, and 2026 Catalysts Underpin Buy Rating - TipRanks
Insmed jumps after forecasting preliminary 2025 revenue above estimates - TradingView — Track All Markets
Insmed Incorporated Provides Revenue Guidance for the Full Year 2025 - marketscreener.com
Insmed shares jump on robust BRINSUPRI rollout and ARIKAYCE outperformance - MSN
Insmed (INSM) Projects Arikayce Revenue of $450M-$470M for FY26 - GuruFocus
Insmed (INSM) Expects Significant Revenue Growth by FY25 - GuruFocus
Insmed (INSM) Plans Multiple Product Launches and Trials Through 2026 - GuruFocus
Insmed stock rises after strong BRINSUPRI launch, ARIKAYCE revenue beat By Investing.com - Investing.com UK
Insmed reports strong Q4 revenue for BRINSUPRI and ARIKAYCE By Investing.com - Investing.com UK
Insmed Inc Provides Business Update at J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Insmed Inc (INSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Insmed Inc 주식 (INSM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lewis William | Chair and CEO |
Jan 12 '26 |
Sale |
169.00 |
19,215 |
3,247,349 |
306,891 |
| Flammer Martina M.D. | Chief Medical Officer |
Jan 09 '26 |
Sale |
186.19 |
1,887 |
351,341 |
84,907 |
0.03%
2.76%
자본화:
|
볼륨(24시간):